-
EP2988826
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP2988826
| EP2988826 - IL4 CONJUGATED TO ANTIBODIES AGAINST EXTRACELLULAR MATRIX COMPONENTS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 04.01.2019 Database last updated on 14.06.2024 | |
| Former | Examination is in progress Status updated on 23.06.2017 | Most recent event Tooltip | 04.01.2019 | Application deemed to be withdrawn | published on 06.02.2019 [2019/06] | Applicant(s) | For all designated states Philogen S.p.A. Piazza La Lizza, 7 53100 Siena / IT | [2016/09] | Inventor(s) | 01 /
HEMMERLE, Teresa Lettgräbli 1 CH-9490 Vaduz / LI | 02 /
NERI, Dario Zihl Strasse 35 CH-8107 Buchs / CH | [2016/09] | Representative(s) | Mewburn Ellis LLP Aurora Building Counterslip Bristol BS1 6BX / GB | [N/P] |
| Former [2016/09] | Keirstead, Tanis Evelyne, et al Mewburn Ellis LLP City Tower 40 Basinghall Street London EC2V 5DE / GB | Application number, filing date | 14708835.5 | 28.02.2014 | [2016/09] | WO2014EP53998 | Priority number, date | GB20130007599 | 26.04.2013 Original published format: GB 201307599 | GB20130018043 | 11.10.2013 Original published format: GB 201318043 | GB20130020647 | 22.11.2013 Original published format: GB 201320647 | [2016/09] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014173570 | Date: | 30.10.2014 | Language: | EN | [2014/44] | Type: | A1 Application with search report | No.: | EP2988826 | Date: | 02.03.2016 | Language: | EN | The application published by WIPO in one of the EPO official languages on 30.10.2014 takes the place of the publication of the European patent application. | [2016/09] | Search report(s) | International search report - published on: | EP | 30.10.2014 | Classification | IPC: | A61P37/00, A61P19/02, A61P17/06, A61P3/10, A61K47/48 | [2016/09] | CPC: |
A61K38/2026 (EP,US);
C07K14/5406 (EP,US);
A61K31/573 (US);
A61K39/3955 (EP,US);
A61K39/39558 (EP);
A61K47/6813 (EP,US);
A61K47/6851 (EP,US);
A61P15/00 (EP);
A61P17/06 (EP);
A61P19/02 (EP);
A61P35/00 (EP);
C07K14/5428 (EP);
C07K14/5434 (EP);
C07K14/55 (EP);
C07K14/70578 (EP);
C07K16/18 (EP,US);
C07K16/40 (EP);
A61K2039/505 (EP,US);
A61K2039/545 (EP);
A61K38/00 (EP);
C07K2317/21 (US);
C07K2317/565 (US);
C07K2317/626 (EP,US);
C07K2317/76 (US);
| C-Set: |
A61K39/3955, A61K2300/00 (EP)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/09] | Title | German: | ZU ANTIKÖRPERN GEGEN EXTRAZELLULÄRE MATRIXKOMPONENTEN KONJUGIERTES IL4 | [2016/09] | English: | IL4 CONJUGATED TO ANTIBODIES AGAINST EXTRACELLULAR MATRIX COMPONENTS | [2016/09] | French: | IL-4 CONJUGUÉE À DES ANTICORPS CONTRE DES COMPOSANTS DE LA MATRICE EXTRACELLULAIRE | [2016/09] | Entry into regional phase | 13.11.2015 | National basic fee paid | 13.11.2015 | Designation fee(s) paid | 13.11.2015 | Examination fee paid | Examination procedure | 11.12.2014 | Request for preliminary examination filed International Preliminary Examining Authority: EP | 13.11.2015 | Examination requested [2016/09] | 14.06.2016 | Amendment by applicant (claims and/or description) | 22.06.2017 | Despatch of a communication from the examining division (Time limit: M04) | 25.10.2017 | Reply to a communication from the examining division | 01.09.2018 | Application deemed to be withdrawn, date of legal effect [2019/06] | 27.09.2018 | Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time [2019/06] | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 22.06.2017 | Fees paid | Renewal fee | 24.02.2016 | Renewal fee patent year 03 | 27.01.2017 | Renewal fee patent year 04 | Penalty fee | Additional fee for renewal fee | 28.02.2018 | 05 M06 Not yet paid |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]WO0110912 (LEXIGEN PHARM CORP [US]) [A] 1-9,18-25,56-60 * page 16, line 14 - line 16; example 17 *; | [A]WO2010011697 (IMMUNOMEDICS INC [US], et al) [A] 1-9,18-25,56-60 * claims 31,45 *; | [Y]WO2013014149 (PHILOGEN SPA [IT], et al) [Y] 3,9,18-20 * claim 12; sequence 32 *; | [XAY] - Teresa Hemmerle ET AL, "Doktorandentag -Spring Session 2013 2", Zürich, (20130208), pages 1 - 6, URL: http://www.pharma.ethz.ch/box_feeder/Doktorandentag2013.pdf, (20140602), XP055121083 [X] 1,2,4-8,21-25,56-60 * the whole document * [A] 85-89 [Y] 3,9,18-20 | [Y] - N. PASCHE ET AL, "The Antibody-Based Delivery of Interleukin-12 to the Tumor Neovasculature Eradicates Murine Models of Cancer in Combination with Paclitaxel", CLINICAL CANCER RESEARCH, (20120612), vol. 18, no. 15, doi:10.1158/1078-0432.CCR-12-0282, ISSN 1078-0432, pages 4092 - 4103, XP055039930 [Y] 3,9,18-20 * the whole document * DOI: http://dx.doi.org/10.1158/1078-0432.CCR-12-0282 | [XPI] - TERESA HEMMERLE ET AL, "The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer", INTERNATIONAL JOURNAL OF CANCER, (20130702), vol. 134, no. 2, doi:10.1002/ijc.28359, ISSN 0020-7136, pages 467 - 477, XP055121200 [XP] 1-9,18-25,56-60 * the whole document * [I] 26-51,85-95 DOI: http://dx.doi.org/10.1002/ijc.28359 | [Y] - ROLAND E. KONTERMANN, "Antibody-cytokine fusion proteins", ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, (20121001), vol. 526, no. 2, doi:10.1016/j.abb.2012.03.001, ISSN 0003-9861, pages 194 - 205, XP055121202 [Y] 3,9,18-20 * the whole document * DOI: http://dx.doi.org/10.1016/j.abb.2012.03.001 | [A] - TRZPIS MONIKA ET AL, "Epithelial cell adhesion molecule - More than a carcinoma marker and adhesion molecule", AMERICAN JOURNAL OF PATHOLOGY; [10640], ELSEVIER INC, US, vol. 171, no. 2, doi:10.2353/AJPATH.2007.070152, ISSN 0002-9440, (20070801), pages 386 - 395, (20070628), XP002581967 [A] 1-9,18-25,56-60 * the whole document * DOI: http://dx.doi.org/10.2353/AJPATH.2007.070152 | [A] - SABINE DENZEL ET AL, "MMP7 is a target of the tumour-associated antigen EpCAM", INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY, (20120913), vol. 93, no. 5, doi:10.1111/j.1365-2613.2012.00826.x, ISSN 0959-9673, pages 341 - 353, XP055121392 [A] 1-9,18-25,56-60 * the whole document * DOI: http://dx.doi.org/10.1111/j.1365-2613.2012.00826.x | [IAY] - FONS A VAN DE LOO ET AL, "Immunocytokines: the long awaited therapeutic magic bullet in rheumatoid arthritis?", ARTHRITIS RESEARCH & THERAPY, England, (20091106), vol. 11, no. 6, doi:10.1186/ar2835, ISSN 1478-6362, pages 1 - 2, XP055121193 [I] 1-9,18-21,26-44 * the whole document * [A] 85-89 [Y] 1-9,18-21,26-29 DOI: http://dx.doi.org/10.1186/ar2835 | [IA] - SCHWAGER KATHRIN ET AL, "Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis", ARTHRITIS RESEARCH AND THERAPY, BIOMED CENTRAL, LONDON, GB, (20090925), vol. 11, no. 5, doi:10.1186/AR2814, ISSN 1478-6354, page R142, XP021065243 [I] 1-9,18-21,26-43 * the whole document * [A] 85-89 DOI: http://dx.doi.org/10.1186/ar2814 | [YA] - Kathrin Annina Schwager, "Recombinant antibodies for the imaging and treatment of rheumatoid arthritis and endometriosis", (20100101), pages 1 - 106, URL: http://e-collection.library.ethz.ch/eserv/eth:1816/eth-1816-02.pdf, (20140603), XP055121189 [Y] 1-9,18-21,26-29,44-51 * pages 6,7,34 * * pages 37-42 * * pages 44-51 * * pages 74,93 * [A] 85-89 | [Y] - MARTIN R, "Interleukin 4 treatment of psoriasis: are pleiotropic cytokines suitable therapies for autoimmune diseases?", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, (20031201), vol. 24, no. 12, doi:10.1016/J.TIPS.2003.10.006, ISSN 0165-6147, pages 613 - 616, XP004476611 [Y] 44-47 * the whole document * DOI: http://dx.doi.org/10.1016/j.tips.2003.10.006 | [A] - LOO VAN DE F A J ET AL, "Gene therapy for rheumatoid arthritis. Lessons from animal models, including studies on interleukin-4, interleukin-10, and interleukin-1 receptor antagonist as potential disease modulators", RHEUMATIC DISEASES CLINICS OF NORTH AMERICA, W.B. SAUNDERS, PHILADELPHIA, PA, US, (20020201), vol. 28, no. 1, doi:10.1016/S0889-857X(03)00073-5, ISSN 0889-857X, pages 127 - 149, XP009028686 [A] 85-89 * the whole document * DOI: http://dx.doi.org/10.1016/S0889-857X(03)00073-5 | [A] - ARREAZA G A ET AL, "Interleukin-4: Potential immunoregulatory agent in therapy of insulin-dependent diabetes mellitus", EMBASE, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, (1996), Database accession no. EMB-1996306612, XP002729061 [A] 34,90-95 * abstract * | [ ] - ARREAZA G A ET AL, "Interleukin-4: Potential immunoregulatory agent in therapy of insulin-dependent diabetes mellitus", CLINICAL IMMUNOTHERAPEUTICS 1996 NZ, (1996), vol. 6, no. 4, ISSN 1172-7039, pages 251 - 260, XP002086507 | [Y] - URCELAY E ET AL, "Role of interleukin 4 in Spanish multiple sclerosis patients", JOURNAL OF NEUROIMMUNOLOGY, ELSEVIER SCIENCE PUBLISHERS BV, NL, vol. 168, no. 1-2, ISSN 0165-5728, (20051101), pages 164 - 167, (20051101), XP027673107 [Y] 48-51 * the whole document * | Examination | - Leo A. B. Joosten ET AL, "Role of interleukin-4 and interleukin-10 in murine collagen-induced arthritis. Protective effect of interleukin-4 and interleukin-10 treatment on cartilage destruction", Arthritis & Rheumatism, (19970201), vol. 40, no. 2, doi:10.1002/art.1780400209, ISSN 0004-3591, pages 249 - 260, XP055033715 DOI: http://dx.doi.org/10.1002/art.1780400209 |